易普利姆玛
无容量
医学
黑色素瘤
肿瘤科
内科学
免疫疗法
癌症研究
癌症
作者
Jedd D. Wolchok,Vanna Chiarion‐Sileni,Piotr Rutkowski,C. Lance Cowey,Dirk Schadendorf,John Wagstaff,Paola Queirolo,Reinhard Dummer,Marcus O. Butler,Andrew G. Hill,Michael A. Postow,C. Gaudy‐Marqueste,Theresa Medina,Christopher D. Lao,John R. Walker,Iván Márquez‐Rodas,John B.A.G. Haanen,Massimo Guidoboni,Michele Maio,Patrick Schöffski
标识
DOI：10.1056/nejmoa2407417
摘要
Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given that patients with advanced melanoma are living longer than 7.5 years, longer-term data were needed to address new clinically relevant questions.
科研通智能强力驱动
Strongly Powered by AbleSci AI
bc
斯寜
Li
归尘
失眠天亦
zho
狂野的锦程
Leung
iNk
jyy
andrele
eee
核桃
HT
平常的毛豆
YifanWang
morena
MchemG
mmyhn
pluto
皖公网安备34019202002308
